SemaglutideRx
GLP-1 Receptor Agonist

SemaglutideRx
GLP-1 Receptor Agonist
TirzepatideRx
Dual GLP-1 + GIP Receptor Agonist
Semaglutide ODT PillsRx
GLP-1 Receptor Agonist - Oral Dissolving Tablet
Tirzepatide ODT PillsRx
Dual GLP-1 + GIP Receptor Agonist - Oral Dissolving Tablet
Men's Complete Hair Growth PillRx
Minoxidil, Finasteride, Biotin
Men's Advanced Hair SprayRx
Minoxidil, Finasteride, Fluocinolone, Tretinoin
Women's Premium Hair SprayRx
Minoxidil, Tretinoin, Fluocinolone, Biotin, Melatonin
Women's Complete Hair Growth PillRx
Minoxidil, Vitamin E, Biotin
Written by Join Luma Team
November 8, 2026 · 8 min read

The Wegovy injection reference schedule starts with 0.25 → 0.5 → 1 → 1.7 → 2.4 mg weekly, with four weeks at each escalation step.
Your Join Luma clinician sets your compounded semaglutide schedule; do not change your dose from this table.
The Wegovy injection label describes 0.25 → 0.5 → 1 → 1.7 → 2.4 mg weekly, with four weeks at each escalation step. The table uses four-week blocks rather than calendar months: four weekly injections make a block, and a calendar month can contain an extra injection day. It shows a progression, not a promise that every patient advances on exactly these dates.
| Four-week block | Dose once weekly | Purpose |
|---|---|---|
| 1: weeks 1–4 | 0.25 mg | Starting step |
| 2: weeks 5–8 | 0.5 mg | Escalation |
| 3: weeks 9–12 | 1 mg | Escalation |
| 4: weeks 13–16 | 1.7 mg | Escalation; also an adult maintenance option |
| 5 onward: week 17+ | 2.4 mg | Recommended maintenance in this label; 1.7 mg is an alternative |
This table follows the FDA Wegovy prescribing information. It specifically summarizes the November 2024 injectable 2.4-mg regimen, not every later formulation, indication or dose presentation. Ozempic has different labeled uses and dosing, so its schedule should not be substituted for this one.
Semaglutide affects appetite and digestion. Nausea, vomiting, diarrhea and constipation can occur during treatment, particularly around initiation and dose increases. A low starting dose creates an adjustment period before more medication is introduced. Taking extra medication to accelerate weight loss skips that safety feature and is not a shortcut to a better result.
An early dose can affect appetite without producing a dramatic scale change. Likewise, little nausea does not mean the medicine is inactive. Track how well you can eat, drink and carry out daily activities, along with weight trends. These observations are more useful for a prescribing decision than comparing your first month with somebody else’s most successful month.
NIDDK’s medication overview describes weight-management medication as part of a broader plan that includes eating habits and physical activity. A dose schedule supports that plan; it does not replace it.
The cited Wegovy label allows delaying escalation for four weeks when a dose is not tolerated. Your clinician may reassess symptoms before an increase rather than treating the printed calendar as a deadline. Tell your Join Luma clinician when symptoms start, how long they last and whether they interfere with meals or hydration.
Do not increase because you still feel hungry, and do not decrease solely because the scale moved quickly one week. Appetite, gastrointestinal tolerance and weight change are related but not interchangeable measures. A clinician can decide whether to continue, adjust or investigate another cause of symptoms.
For the adult weight-management regimen discussed here, Wegovy maintenance options are 1.7 or 2.4 mg once weekly. The cited label recommends 2.4 mg, while allowing 1.7 mg according to response and tolerability. The 0.25, 0.5 and 1 mg steps in this schedule are escalation doses, not labeled adult maintenance doses.
A maintenance decision considers more than the fastest possible weight change. Your clinician reviews benefits, side effects, nutritional intake, relevant health conditions and other medications. Reaching a goal can also change the purpose of treatment from losing more weight to preserving progress. Continuing care is still important even when the weekly dose no longer changes.
Same price every dose
A licensed provider reviews your intake. If treatment is appropriate, your medication ships free with expedited two-day delivery.
Get startedMilligrams describe the amount of medication. Milliliters describe the volume of liquid. Syringe units mark a volume on a particular syringe; they are not a universal medication dose. The same number of milligrams can require a different volume when the concentration changes, so a screenshot of someone else’s syringe instructions is not a safe reference.
Use the guide to GLP-1 concentration, mg, mL and units to understand the terms, then ask your clinician or dispensing pharmacy to confirm your actual directions. Never calculate a new injection amount from a brand table alone. Check a new vial against its own label even if the medication name is unchanged.
“Talk to your doctor if you have questions about your medicines.”
The FDA-approved brand injection schedules discussed here are reference information, not a prescription for a compounded formulation. Join Luma offers compounded medications, which are not FDA-approved and were not the products studied in brand clinical trials. Their dose, concentration, directions and beyond-use date must come from your own prescription label and clinician. The FDA explains these distinctions.
Keep your injection date, prescribed dose, symptoms and remaining supply in one place. Before a refill, send your Join Luma clinician the information needed to review whether the current step remains appropriate. Request clarification before injecting if the written dose and syringe directions appear inconsistent. Store the medication according to the pharmacy label rather than borrowing a brand pen’s storage allowance.
For a missed injection or a longer interruption, follow your own label and contact the prescribing clinician. Brand products have specific missed-dose instructions, but a gap can also change tolerability. Do not double an injection or resume an old higher dose on your own. The missed-dose guide explains what information to have ready.
Seek urgent care for severe or persistent abdominal pain, repeated vomiting with dehydration, or other severe symptoms. Call 911 for trouble breathing, swelling of the face or throat, or another potentially life-threatening allergic reaction. Routine scheduling questions belong with your clinician, but serious symptoms should not wait for a portal reply. Tell the clinician about pregnancy plans, diabetes medicines and planned procedures before making treatment changes.
Your Join Luma clinician sets your schedule after reviewing your medical history and response. An educational brand chart does not authorize a change to your compounded prescription. If you are transferring care, share the previous prescription, concentration, last injection date and any side effects so the clinician can assess continuity safely.
Join Luma uses the same price every dose: the price does not change when your dose changes. Plans include clinician oversight, medication if prescribed, necessary supplies and shipping, with no membership fees. Commitment length and patient plan category can affect pricing separately from dose; review the current plan options rather than assuming a dose increase changes your bill.
| Treatment | Starting at | 3-month total |
|---|---|---|
| Compounded semaglutide | $99/mo | $297 upfront |
| Compounded tirzepatide | $149/mo | $447 upfront |
| Compounded semaglutide ODT | $159/mo | $477 upfront |
| Compounded tirzepatide ODT | $179/mo | $537 upfront |
Current GLP users can access the same injection starting rates with a six-month plan: compounded semaglutide $99/mo ($594 upfront); compounded tirzepatide $149/mo ($894 upfront). Pay upfront or use Affirm, Klarna or Afterpay to split the payments, subject to eligibility and approval. Other billing options and oral current-user prices are listed on the pricing page. Treatment requires provider approval.
For refill logistics or questions about a message, contact support@joinluma.com or the patient portal. Clinical changes still require the prescribing clinician. Learn more about weekly injection care if you are preparing for treatment rather than adjusting an existing prescription.
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality before marketing. Brand-product study results describe the FDA-approved products studied. A licensed clinician decides whether treatment is appropriate; follow your prescription label and your clinician's directions.
This article is for educational purposes only and is not intended to provide medical advice, diagnosis, or treatment. Individual treatment decisions should be made with a licensed healthcare provider.
The reference schedule uses four-week blocks, not calendar months. Your prescription and injection dates determine when a clinician-approved change occurs.
Do not accelerate semaglutide on your own. The brand escalation intervals support tolerability, and your Join Luma clinician must approve changes.
Tell your clinician about your progress and side effects. The Wegovy adult weight-management maintenance options in the cited regimen are 1.7 or 2.4 mg weekly.
Join Luma offers the same price every dose. Plan category and commitment length are separate pricing considerations.
Not without checking the new prescription label. Concentration and syringe type determine the relationship between medication dose and injection volume.
No. These are brand weekly injection reference schedules, not instructions for oral medication or compounded daily dissolving tablets.
Share this article